A Major Shortcoming in the Public Health Legacy of the Obama Administration.

Abstract

The author reflects on U.S. President Barack Obama's public health legacy in relation to the practices of America's Food and Drug Administration (FDA) during Obama's tenure as the nation's leader. The FDA's approval of medical products based on lower standards of scientific evidence is examined, along with FDA Commissioner Margaret Hamburg's promises regarding the agency's approval process and governmental transparency. FDA reforms of medical device standards are assessed.